{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = 4-[(''Z'')-1-[4-[2-(Dimethylamino)ethoxy]phenyl]-2-(4-propan-2-ylphenyl)but-1-enyl]phenol
| image = Miproxifene.svg
| width = 250

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!-- Identifiers -->
| CAS_number_Ref = 
| CAS_number = 129612-87-9
| CAS_supplemental = 
| ATC_prefix = 
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 3037015
| IUPHAR_ligand = 
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 2300875
| UNII = BGJ4Z7930W
| KEGG = 
| ChEBI = 
| ChEMBL = 2074961

<!--Chemical data-->
| C=29 | H=35 | N=1 | O=2
| SMILES = CC/C(=C(\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=C(C=C3)C(C)C
| StdInChI_Ref = 
| StdInChI = 1S/C29H35NO2/c1-6-28(23-9-7-22(8-10-23)21(2)3)29(24-11-15-26(31)16-12-24)25-13-17-27(18-14-25)32-20-19-30(4)5/h7-18,21,31H,6,19-20H2,1-5H3/b29-28-
| StdInChIKey_Ref = 
| StdInChIKey = FVVPWVFWOOMXEZ-ZIADKAODSA-N
| synonyms = DP-TAT-59
}}

'''Miproxifene''' ([[International Nonproprietary Name|INN]]) (former developmental code name '''DP-TAT-59''') is a [[nonsteroidal]] [[selective estrogen receptor modulator]] (SERM) of the [[triphenylethylene]] group that was never marketed.<ref name="AdisInsight">http://webcache.googleusercontent.com/search?q=cache:FyhxGXFiLogJ:adisinsight.springer.com/drugs/800000796+&cd=1&hl=en&ct=clnk&gl=us</ref><ref name="StellaBorchardt2007">{{cite book|author1=Valentino Stella|author2=Ronald Borchardt|author3=Michael Hageman |author4=Reza Oliyai |author5=Hans Maag |author6=Jefferson Tilley|title=Prodrugs: Challenges and Rewards|url=https://books.google.com/books?id=qkjHxX5TgHEC&pg=PA168|date=12 March 2007|publisher=Springer Science & Business Media|isbn=978-0-387-49782-2|pages=168–169}}</ref> It is a [[chemical derivative|derivative]] of [[afimoxifene]] (4-hydroxytamoxifen) in which an additional 4-[[isopropyl group]] is present in the β-[[phenyl group|phenyl ring]].<ref name="OettelSchillinger2012">{{cite book|author1=Michael Oettel|author2=Ekkehard Schillinger|title=Estrogens and Antiestrogens I: Physiology and Mechanisms of Action of Estrogens and Antiestrogens|url=https://books.google.com/books?id=0BfrCAAAQBAJ&pg=PA58|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-58616-3|pages=58–60}}</ref> The drug has been found to be 3- to 10-fold more potent than [[tamoxifen]] in inhibiting [[breast cancer]] [[cell growth]] in ''[[in vitro]]'' models.<ref name="AdisInsight" /><ref name="KelloffHawk2008">{{cite book|author1=Gary J. Kelloff|author2=Ernest T. Hawk|author3=Caroline C. Sigman|title=Cancer Chemoprevention: Volume 2: Strategies for Cancer Chemoprevention|url=https://books.google.com/books?id=ldyg4-cem9UC&pg=PA251|date=17 August 2008|publisher=Springer|isbn=978-1-59259-768-0|pages=251–}}</ref><ref name="OttowWeinmann2008">{{cite book|author1=Eckhard Ottow|author2=Hilmar Weinmann|title=Nuclear Receptors as Drug Targets|url=https://books.google.com/books?id=iATfLbPgRugC&pg=PA90|date=8 September 2008|publisher=John Wiley & Sons|isbn=978-3-527-62330-3|pages=90–}}</ref> Miproxifene is the [[active metabolite]] of [[miproxifene phosphate]] (TAT-59), a [[phosphate]] [[ester]] and [[prodrug]] of miproxifene that was developed to improve its [[water solubility]].<ref name="AdisInsight" /><ref name="StellaBorchardt2007" /><ref name="StromgaardKrogsgaard-Larsen2016">{{cite book|author1=Kristian Stromgaard|author2=Povl Krogsgaard-Larsen|author3=Ulf Madsen|title=Textbook of Drug Design and Discovery, Fifth Edition|url=https://books.google.com/books?id=FcLBDAAAQBAJ&pg=PA162|date=19 August 2016|publisher=CRC Press|isbn=978-1-4987-0279-9|pages=162–}}</ref><ref name="YangYeh2013">{{cite book|author1=Hsiu-Chiung Yang|author2=Wu-Kuang Yeh|author3=J. R. McCarthy|title=Enzyme Technologies: Pluripotent Players in Discovering Therapeutic Agent|url=https://books.google.com/books?id=-nUqAgAAQBAJ&pg=PA166|date=22 November 2013|publisher=Wiley|isbn=978-1-118-73989-1|pages=166–}}</ref> Miproxifene phosphate was under development for the treatment of breast cancer and reached [[Phases of clinical research#Phase III|phase III]] [[clinical trial]]s for this indication but development was discontinued.<ref name="AdisInsight" />

==References==
{{reflist|30em}}

{{Estrogen receptor modulators}}

[[Category:Alcohols]]
[[Category:Amines]]
[[Category:Hormonal antineoplastic drugs]]
[[Category:Human drug metabolites]]
[[Category:Selective estrogen receptor modulators]]
[[Category:Triphenylethylenes]]


{{genito-urinary-drug-stub}}
{{antineoplastic-drug-stub}}